Company research
Contineum Therapeutics, Inc.
CIK 1855175Updated Sep 24, 2026
SecurityCTNM · NASDAQ · equity
CTNM price & chart
Loading TradingView…
NASDAQ:CTNM on TradingView ↗About the company
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit www.contineum-tx.com.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A filing
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
4 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 276,642,000Source | 212,847,000Source | 130,386,000Source |
| Property, Plant and Equipment, NetUSD | 830,000Source | 989,000Source | 678,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 75,603,000Source | 21,943,000Source | 15,526,000Source |
| Assets, CurrentUSD | 267,917,000Source | 206,388,000Source | 127,706,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,021,000Source | 1,628,000Source | 2,516,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,639,000Source | 5,467,000Source | 719,000Source |
| Other Assets, NoncurrentUSD | 256,000Source | 3,000Source | 1,283,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 15,653,000Source | 14,781,000Source | 5,702,000Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 438,072,000Source | 315,371,000Source | 7,098,000Source |
| Retained Earnings (Accumulated Deficit)USD | -177,380,000Source | -117,402,000Source | -75,144,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 260,000Source | 71,000Source | 108,000Source |
| Stockholders' Equity Attributable to ParentUSD | 260,989,000Source | 198,066,000Source | -67,936,000Source |
| Liabilities and EquityUSD | 276,642,000Source | 212,847,000Source | 130,386,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 9,744,000Source | 9,974,000Source | 5,484,000Source |
| Operating Lease, Liability, CurrentUSD | 2,341,000Source | 1,452,000Source | 464,000Source |
| Accounts Payable, CurrentUSD | 1,016,000Source | 1,811,000Source | 635,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,909,000Source | 4,807,000Source | 108,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 110,000Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 6,387,000Source | 6,711,000Source | 4,385,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 262,900,000Source | 204,800,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 323,000Source | 258,000Source | 195,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,038,000Source | 6,804,000Source | 2,219,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts PayableUSD | -869,000Source | 1,141,000Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -55,312,000Source | -32,845,000Source | 19,349,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -3,713,000Source | -69,739,000Source | -65,568,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 231,000Source | 514,000Source | 414,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 112,685,000Source | 109,001,000Source | 56,176,000Source |
| Repayments of Long-term DebtUSD | — | 0Source | 3,750,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 53,660,000Source | 6,417,000Source | 9,957,000Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 0Source | 150,000Source |
| Income Taxes Paid, NetUSD | 1,000Source | 0Source | 450,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 10,038,000Source | 200,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 0Source | -198,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 262,900,000Source | 204,800,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | 16,000Source | 0Source |
| General and Administrative ExpenseUSD | 16,537,000Source | 12,472,000Source | 6,320,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 450,000Source |
| InterestExpenseNonoperatingUSD | — | 0Source | 208,000Source |
| Investment Income, InterestUSD | 8,246,000Source | 8,905,000Source | 4,606,000Source |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 12,000Source | 5,000Source | -19,000Source |
| Net Income (Loss) Attributable to ParentUSD | -59,978,000Source | -42,258,000Source | 22,720,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -42,258,000Source | 3,146,000Source |
| Nonoperating Income (Expense)USD | 8,081,000Source | 8,636,000Source | 7,093,000Source |
| Operating ExpensesUSD | 68,059,000Source | 50,894,000Source | 33,923,000Source |
| Operating Lease, ExpenseUSD | 1,700,000Source | 1,100,000Source | — |
| Other Nonoperating Income (Expense)USD | -165,000Source | -163,000Source | -177,000Source |
| Proceeds from Issuance of Common StockUSD | — | 108,211,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | 219,000Source | 405,000Source | 159,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | — | 0Source | 50,000,000Source |
| Operating Income (Loss)USD | -68,059,000Source | -50,894,000Source | 16,077,000Source |
| Other Nonoperating Income (Expense)USD | -165,000Source | -163,000Source | -177,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -60,143,000Source | -42,258,000Source | 23,170,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 450,000Source |
| Net Income (Loss) Attributable to ParentUSD | -59,978,000Source | -42,258,000Source | 22,720,000Source |
| Earnings Per Share, BasicUSD per share | -2.17Source | -2.18Source | 1.36Source |
| Earnings Per Share, DilutedUSD per share | -2.17Source | -2.18Source | 0.08Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 27,700,855Source | 19,352,859Source | 2,308,972Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 27,700,855Source | 19,352,859Source | 3,395,514Source |
| Interest Expense (non-operating)USD | — | 0Source | 208,000Source |
| Additional Financial Items | |||
| General and Administrative ExpenseUSD | 16,537,000Source | 12,472,000Source | 6,320,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -60,143,000Source | — | — |
| Investment Income, InterestUSD | 8,246,000Source | 8,905,000Source | 4,606,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -42,258,000Source | 3,146,000Source |
| Nonoperating Income (Expense)USD | 8,081,000Source | 8,636,000Source | 7,093,000Source |
| Operating ExpensesUSD | 68,059,000Source | 50,894,000Source | 33,923,000Source |
| Operating Lease, ExpenseUSD | 1,700,000Source | 1,100,000Source | — |
| Research and Development ExpenseUSD | 51,522,000Source | 38,422,000Source | 27,603,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | 0Source | 19,574,000Source |
Filing attachments
q220268kex991.htm · 8-K · 2026-07-30
EX-99.1 2 q220268kex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO - July 30, 2026 - Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results an…
Read attachment ↗q120268kex991.htm · 8-K · 2026-05-05
EX-99.1 2 q120268kex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO - May 5, 2026 - Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2026 financial results and af…
Read attachment ↗a8-kpaindataex991.htm · 8-K · 2026-04-30
EX-99.1 2 a8-kpaindataex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM ITS EXPLORATORY PIPE-791 PHASE 1B TRIAL IN CHRONIC PAIN - The trial achieved its primary endpoint demonstrating favorable safety and tolerability - Encouraging trends observed across multiple exploratory efficacy endpoints including improvements in measures of pain and other functional patient-reported outcomes - Results support further evaluation of PIPE-791 for the p…
Read attachment ↗a2026_marchx8kxex991.htm · 8-K · 2026-03-05
EX-99.1 4 a2026_marchx8kxex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES - Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 SAN DIEGO - March 5, 202…
Read attachment ↗